FEB 17, 2021 8:17 AM PST

On the path to eradicating racial bias in melanoma

New research published today in the American Association for Cancer Research journal Blood Cancer Discovery proposes an approach aimed to address racial discrepancies in clinical trials for multiple myeloma. Multiple myeloma is a blood cancer that reports a death rate twice as high in African Americans as compared to white Americans. The recommendations outlined in the paper from Dana-Farber Cancer Institute, the FDA, and AACR, intend to improve the representation of African American patients in clinical trials.

Although African Americans are more than twice as likely as white Americans to be diagnosed with multiple myeloma and to die from it, enrollment of African Americans in clinical trials has decreased by 3.5% in the last decade. African Americans account for 20% of people diagnosed with myeloma but made up only 4.5% of patients in new drug and biological license applications for myeloma from 2003-2017.

"There hasn't been as much progress in African Americans as there has been in other groups," says Kenneth C. Anderson, MD, the corresponding author of the study from Dana-Farber Cancer Institute. "The number of African Americans enrolled in clinical trials of novel agents or treatments of multiple myeloma has been tragically low. When they have enrolled, their outcome to treatment with novel therapies has been the same or even better than other patients," he commented.

The recommendations that the paper puts forth include the following, as reported by Dana Farber:

  • “Broadening eligibility criteria whenever possible. For example, study criteria that reject patients with conditions like high blood pressure and kidney disease may disproportionately exclude African Americans. Including such patients may allow researchers to collect more data in racial and ethnic subpopulations.”
  • “Requiring trial sponsors to complete a diversity study plan that sets targets for enrolling diverse participants.”
  • “Appointing a diversity officer to assist with trial design and recruitment. Trial design should encompass disease subtypes and features most commonly seen in African Americans. Patients and patient advocates involved in the workshop strongly supported the recommendation of a diversity officer "to define strategies that support African American participation in clinical trials." The presence of a diversity officer "will hold researchers and industry accountable to conduct more inclusive and patient-centric trials," the recommendations stressed.”

The recommendations were developed at a workshop that took place last year and involved patients and patient advocates. "Our patients are truly the inspiration and heroes of this collaborative effort to eliminate the glaring issue of racial disparities in clinical trials," says Anderson. "If we can make clinical trials more inclusive and representative of real-world patients, we may not only enhance participation of African American patients, but also provide a paradigm for new drug development more broadly."

Sources: Blood Cancer Discovery, Dana Farber

About the Author
BA Environmental Studies
Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
AUG 25, 2022
Cancer
Nearly Half of Global Cancer Deaths Attributed to Behavioral Risk Factors
AUG 25, 2022
Nearly Half of Global Cancer Deaths Attributed to Behavioral Risk Factors
Cancer is a broad description of various related diseases resulting from abnormal and excessive cell growth.  While ...
OCT 06, 2022
Chemistry & Physics
2022 Nobel Prize in Chemistry
OCT 06, 2022
2022 Nobel Prize in Chemistry
It’s that time of year again! Three scientists, Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless, were a ...
OCT 25, 2022
Cancer
Study Identifies Patients at High Risk of Breast Cancer Metastasis
OCT 25, 2022
Study Identifies Patients at High Risk of Breast Cancer Metastasis
Central nervous system metastasis (mCNS) accounts for most brain and spinal cord tumors.  While recent advances hav ...
OCT 28, 2022
Cancer
Pancreatic Tumor Growth and Metastasis Inhibited
OCT 28, 2022
Pancreatic Tumor Growth and Metastasis Inhibited
Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive type of pancreatic cancer, has a very poor prognosis due, a ...
NOV 02, 2022
Clinical & Molecular DX
New Genetic Variants Identified as Risk Factors for Ovarian Cancer
NOV 02, 2022
New Genetic Variants Identified as Risk Factors for Ovarian Cancer
Ovarian cancer is a complex disease resulting from mutated cells in the ovaries. As the cells multiply, they can invade ...
NOV 17, 2022
Drug Discovery & Development
Implantable Pump Delivers Chemotherapy Directly to the Brain
NOV 17, 2022
Implantable Pump Delivers Chemotherapy Directly to the Brain
An implantable pump can bypass the blood-brain barrier and deliver chemotherapy to specific brain areas. The correspondi ...
Loading Comments...